Clinical trials: House Dust Mite Allergy
Allergic Asthma, Allergy to House Dust
Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Mite Allergic Subjects With Asthma
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne house dust mite allergen inducing bronchial response in asthmatic subjects allergic to mite, during allergen exposures in…
- Conditions
- Allergic Asthma, Allergy to House Dust, Allergy
- Trial name
- NCT04663880
- Testing
- Exposure to three concentrations of HDM allergen in EEC, Exposure to a single concentration of HDM allergen in EEC
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Alyatec
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is achieved by 90% of the patients with less than 20% of the injections giving rise to a swelling of > 5 cm and the optimal regimen to reach…
- Trial name
- NCT00973453
- Testing
- PURETHAL Mites 20,000 AUeq/ml
- Where
- 6 sites in Germany
- Volunteers
- 48 people
- Sponsor
- HAL Allergy
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Adolescent Mite Allergy Safety Evaluation
This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.
- Trial name
- AMASE (NCT04541004)
- Testing
- HDM SLIT-tablet
- Where
- 27 sites in Czechia, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- ALK-Abelló A/S
House Dust Mite Allergy, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- House Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT05400811
- Testing
- MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL)
- Where
- 16 sites in Spain
- Volunteers
- 400 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy
- Trial name
- MM09 (NCT02661854)
- Testing
- MM09 Mannosylated 5.000 subcutaneous, MM09 Mannosylated 10.000 subcutaneous, MM09 Mannosylated 30.000 subcutaneous
- Where
- 14 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Inmunotek S.L.
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Type I Allergy
Design of Optimally-diagnostic Skin Test Solutions for Diagnosis of Sensitisation to a Pollen and Dust Mite Mixture.
Multicenter Skin Prick Test
- Trial name
- NCT00665483
- Testing
- Skin Prick Test
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Atopic Dermatitis
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis
- Trial name
- NCT00310492
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 154 people
- Sponsor
- ALK-Abelló A/S
Allergy and Immunology
Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects
This is a single-center, randomized, double-blind, placebo-controlled, single-dose, dose- escalation study in otherwise healthy cat-, dust mite-, or Bermuda grass-allergic male and female subjects.
- Trial name
- NCT02559258
- Where
- Australia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tunitas Therapeutics, Inc.
Allergy, Asthma
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60…
- Conditions
- Allergy, Asthma, Rhinitis
- Trial name
- NCT02596321
- Testing
- Mitizax
- Where
- 9 sites in Belarus, Russia
- Volunteers
- 112 people
- Sponsor
- Abbott
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Allergic Rhinitis
Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen
A Multi-Center Study Evaluating the Nasal Allergic Symptomatology Induced by a Nasal Allergen Challenge (NAC) in a Dust Mite Population
- Trial name
- NCT01936818
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- ORA, Inc.
Allergic Asthma
Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite
- Trial name
- NCT00622362
- Testing
- DEPIGOID Dermatophagoides pteronyssinus, Polymerized TOL of Dermatophagoides pteronyssinus
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Laboratorios Leti, S.L.
Rhinoconjunctivitis, Allergies
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.
- Trial name
- NCT00800332
- Testing
- CYT003-QbG10
- Where
- 8 sites in Estonia, Germany and 4 more
- Volunteers
- 300 people
- Sponsor
- Cytos Biotechnology AG
Asthma
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.
- Trial name
- MITRA (NCT01433523)
- Testing
- ALK HDM AIT 6 DU, ALK HDM AIT 12 DU
- Where
- Germany
- Volunteers
- 834 people
- Sponsor
- ALK-Abelló A/S
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.